Pfizer said its trispecific antibody tilrekimig met its primary goal in a mid-stage trial in atopic dermatitis, producing stronger skin clearance than placebo across multiple doses at 16 weeks. In trial data presented at a European medical meeting, Pfizer reported that a substantially higher proportion of patients receiving tilrekimig achieved a 75% reduction in disease scope and severity versus placebo. The company described the efficacy and tolerability profile as validating its multi-pathway approach, with plans to advance tilrekimig into advanced testing. Pfizer also disclosed that it has pushed the program into development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, including a head-to-head study against Dupixent. The competitive landscape matters because Dupixent’s patent protection faces looming expiry in 2031, while other biologics and late-stage candidates continue to vie for share. If results hold in later phases, tilrekimig could become a new competitive entry point in inflammatory disease—particularly if it delivers durable, potentially more convenient dosing compared with current standards.